A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Study sponsor: Ardelyx
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-11-15Actual
Enrollment · participants1559Actual
Source updated2023-06-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.